Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NeoTCR-P1 T-cells |
Synonyms | |
Therapy Description |
NeoTCR-P1 T-cells are autologous T-lymphocytes that are engineered to express patient-specific neoepitope T-cell receptors, which may induce an anti-tumor immune response (Cancer Res 2019;79(13 Suppl):Abstract nr 1433). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NeoTCR-P1 T-cells | NeoTCR-P1 | NeoTCR-P1 T-cells are autologous T-lymphocytes that are engineered to express patient-specific neoepitope T-cell receptors, which may induce an anti-tumor immune response (Cancer Res 2019;79(13 Suppl):Abstract nr 1433). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03970382 | Phase I | NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Suspended | USA | 0 |